- Constitutional Issues
- Consumer Issues
- Economic Development
- Employment and Training
- Financial Institutions
- Government Procurement
- Intellectual Property
- Internal Trade
- International Development
- International Relations
- International Trade
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit, Policies or Program
- FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
Legislative Proposal, Bill or Resolution
- Bill C17 Protecting Canadians from Unsafe Drugs Act - improving adverse event reporting, improve transparency of clinical trials and improve consistency of product labelling
- Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process.
Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
Legislative Proposal, Bill or Resolution, Regulation
- Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
Policies or Program
- Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
- National Immunization Strategy.
Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
- Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
- Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage.
Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
- The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada.
Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
- The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004.
Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
- Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment.
Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
Aboriginal Affairs and Northern Development Canada
Atlantic Canada Opportunities Agency (ACOA)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Employment and Social Development Canada (ESDC)
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs, Trade and Development Canada
Health Canada (HC)
House of Commons
Members of the House of Commons
National Research Council (NRC)
Natural Sciences and Engineering Research Council (NSERC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Works and Government Services Canada
Revenue Canada (RC)
Senate of Canada
Technology Partnerships Canada (TPC)
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.
Responsible officer name and position during the period of this registration
President and Chief Executive Officer
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
7333 Mississauga Road
Mississauga, ON L5N 6L4
Parent Company Information
- GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW89GS
Subsidiary Beneficiary Information
- GlaxoSmithKline Biologicals / GlaxoSmithKline Biologiques
525 Cartier Blvd. W.
Laval, QC H7V 3S8
List of Senior Officers whose lobbying activities represent less than 20% of their Duties
- Rav Kumar,
Vice President Regulatory Affairs and Pharma Development |
No public offices held
- Paul Lirette,
President and Chief Executive Officer |
No public offices held
List of Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties